GLY-200
phase 2drug program · high
Treat obesity, type 2 diabetes, and metabolic disease by noninvasively mimicking duodenal exclusion and bariatric surgery physiology.
Oral, non-absorbed gut-targeted mucin-complexing polymer designed to bind proximal intestinal mucin, enhance mucus barrier function, and create pharmacologic duodenal exclusion through pH-based activation chemistry.
Phase 2 clinical evaluation in type 2 diabetes and a 16-week clinical study in participants with obesity; 2026 publication reported Phase 2a T2D data and preclinical combination data with semaglutide.
Phase 1 healthy-volunteer study reported no safety signals, mild-to-moderate dose-dependent gastrointestinal tolerability events, reduced postprandial glucose and insulin, and increased bile acids, GLP-1, peptide YY, and glicentin at 2.0 g twice daily. Phase 2a T2D data reportedly showed reduced fasting and postprandial blood glucose, improved fasting lipid profiles, and progressive weight loss. Preclinical DIO mouse data suggested additive metabolic effects with semaglutide and reduced weight rebound after GLP-1RA discontinuation.
GLY-200 and GLP-1 receptor agonist combination strategy
preclinicalresearch program · medium
Assess whether GLY-200 can enhance obesity treatment when combined with GLP-1 receptor agonists and support GLP-1RA dose reduction or weight maintenance after GLP-1RA discontinuation.
Diet-induced obesity mouse studies evaluating GLY-200 monotherapy and GLY-200 combined with semaglutide, with metabolic and weight outcomes measured.
The supplied 2026 Molecular Metabolism abstract reports preclinical combination and weight-maintenance findings.
GLY-200 monotherapy improved metabolic parameters in diet-induced obesity mice. Combination with semaglutide produced additive weight loss and metabolic improvements beyond either treatment alone, and GLY-200 blunted weight rebound after GLP-1RA discontinuation.
GLY-200 oral pharmacologic duodenal exclusion therapy
phase 2drug program · high
Treat obesity, type 2 diabetes, and metabolic disease by noninvasively mimicking duodenal exclusion and bariatric surgery physiology.
Orally administered, gut-targeted, non-absorbed polymeric drug designed to bind proximal intestinal mucin, enhance mucus barrier function, and create pharmacologic duodenal exclusion; evaluated in Phase 1 SAD/MAD, Phase 2 type 2 diabetes, and Phase 2 obesity studies.
A 16-week clinical study is evaluating efficacy, safety, and tolerability in participants with obesity; Phase 2a type 2 diabetes data were also reported in the supplied 2026 publication abstract.
Phase 1 showed no safety signals and generally acceptable tolerability at up to 2.0 g twice daily, with reductions in glucose and insulin and increases in bile acids, GLP-1, PYY, and glicentin. Phase 2a type 2 diabetes data reportedly showed reductions in fasting and postprandial blood glucose, improved fasting lipid profiles, and progressive weight loss.
Gut-targeted polymer dynamic barrier platform
exploratoryplatform · medium
Create oral polymer therapeutic candidates that reproduce metabolic benefits associated with gastric bypass surgery and duodenal exclusion devices without invasive surgery or procedures.
Polymer therapeutic platform using mucin-complexing polymers with electrostatic and covalent cross-linkages to mucin glycoproteins, forming extended network structures that alter mucus barrier properties and selectively target the duodenum through pH-based activation chemistry.
Science Advances publication in 2025 described development and screening of targeted oral pharmacologic duodenal exclusion therapy, with GLY-200 emerging as the lead drug candidate.
Screening for physicochemical properties, pharmacokinetics, and efficacy identified GLY-200 as a lead candidate that replicated duodenal exclusion physiology, improved glycemia, reduced body weight, and modulated gut hormones in rodent models.
Gut-targeted polymer therapeutic platform for dynamic barrier duodenal exclusion
exploratoryplatform · high
Create orally delivered polymer therapies that mimic metabolic surgery or duodenal exclusion physiology without invasive surgery or procedures.
Polymer therapeutic platform using mucin-complexing polymers with electrostatic and covalent cross-linkages to alter mucus barrier properties, with selective duodenal targeting via pH-based activation chemistry.
GLY-200 emerged as the lead candidate from screening for physicochemical properties, pharmacokinetics, and efficacy.
Preclinical development identified GLY-200 as a lead drug candidate that replicated duodenal exclusion physiology, improved glycemia, reduced body weight, and modulated gut hormones in rodent models.
